P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer

Farzad, N. and Barati, N. and Momtazi-Borojeni, A. A. and Yazdani, M. and Arab, A. and Razazan, A. and Shariat, S. and Mansourian, M. and Abbasi, A. and Saberi, Z. and Badiee, A. and Jalali, S. A. and Jaafari, M. R. (2019) P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Artificial Cells, Nanomedicine and Biotechnology, 47 (1). pp. 665-673.

[img] Text
P435 HER2 neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer.pdf

Download (1MB)

Abstract

The present study was aimed to develop an effective nanoliposomal vaccine delivery system with P435 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. The nanoliposome formulation composed of DSPC/DSPG/Chol/DOPE and monophosphoryl lipid A was used as an adjuvant. Liposomal formulations were prepared and their physical properties were characterized. Anti-tumoral efficacy of formulations was evaluated by immunization of tumor-bearing BALB/c mice and the generated immune response was studied by using ELISpot and flow cytometry analysis. The results of the study demonstrated Lip + DOPE + P535 formulation caused the lowest tumor size and the longest survival time in TUBO mice model and could make it a promising candidate in developing effective vaccines against HER2-positive breast cancers. © 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Item Type: Article
Additional Information: Export Date: 16 February 2020 Correspondence Address: Jaafari, M.R.; Biotechnology Research Center, Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical SciencesIran; email: Jafarimr@mums.ac.ir
Uncontrolled Keywords: breast cancer cytotoxic T-cell response HER2/neu protein P435 peptide Peptide-conjugated nanoliposomes prophylactic vaccine Diseases Liposomes Mammals Peptides T-cells Tumors Flow cytometry analysis Her2/neu proteins Immune response Liposomal formulation Nanoliposomes T-cell response Vaccine delivery system Vaccines 1,2 distearoyl sn glycero 3 phosphoethanolamine isoleucylarginylglycylarginylisoleucylleucylhistidylaspartylglycylalanyltyrosylserylleucylthreonylleucylglutaminylglycylleucylglycylisoleucylhistidylglycylglycylglycylcysteine liposome macrogol 2000 maleimide peptide phosphoryl lipid A unclassified drug vaccine cancer vaccine epidermal growth factor receptor 2 Erbb2 protein, mouse nanoparticle animal experiment animal model antineoplastic activity Article controlled study female high performance liquid chromatography human epidermal growth factor receptor 2 positive breast cancer immunization liposomal delivery mouse nonhuman polyacrylamide gel electrophoresis survival time tumor volume animal Bagg albino mouse chemistry experimental mammary neoplasm immunology tumor cell line Animals Cancer Vaccines Cell Line, Tumor Mammary Neoplasms, Experimental Mice, Inbred BALB C Nanoparticles Receptor, ErbB-2
Subjects: QZ pathology-neoplasms-Genetics
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib1 lib1
Date Deposited: 21 Jun 2020 05:09
Last Modified: 21 Jun 2020 05:09
URI: http://eprints.mums.ac.ir/id/eprint/18331

Actions (login required)

View Item View Item